Key result
Cardiac myosin inhibitors and emerging targeted therapies expand treatment options for obstructive and non-obstructive HCM.
Why the study?
Since the initial description of hypertrophic cardiomyopathy, there have been minimal management advances, septal reduction therapy is not disease-modifying or suitable for all patients, and guideline-recommended drugs lack strong evidence of benefit.
Design
Review
Authors
Loading...
May broaden HCM treatment choices for clinicians; leaves open need for comparative trials on sequencing and durability.
Cardiac myosin inhibitors and other novel targeted therapies are emerging as promising mainstays of treatment for hypertrophic cardiomyopathy.
Rosenzveig et al. (2023) conducted a review in Hypertrophic cardiomyopathy. Pharmacotherapy (cardiac myosin inhibitors, etc.) was evaluated. Cardiac myosin inhibitors and emerging targeted therapies are expanding the armamentarium of treatment options for both obstructive and non-obstructive hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: